A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study of the Safety and Efficacy of ADC189 Tablets in the Treatment of Influenza A Virus Infection/Influenza B Virus Infection in Adolescents and Adults
Latest Information Update: 24 Jan 2025
At a glance
- Drugs ADC 189 (Primary)
- Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiaxing AnDiCon Biotech
Most Recent Events
- 21 Jan 2025 Status changed from recruiting to completed.
- 06 May 2024 According to Simcere Pharmaceutical Media Release,Primary endpoint (the severity of influenza) has been met.
- 06 May 2024 According to Simcere Pharmaceutical Media Release,Primary endpoint(the safety of study drug) has been met.